JCJihui Chen

Jihui Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jihui Chen has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaohui Huang

    Department of Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

    5 shared publications
  • Huijuan Yao

    Department of Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    4 shared publications
  • Jian Zhang

    4 shared publications
  • Shuhong Bu

    Department of Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    4 shared publications
  • Lixia Li

    Department of Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    3 shared publications
  • Fang Wang

    Department of Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Population Pharmacokinetic Models of Voriconazole in Pediatric Patients: A Systematic Review

    by Xinyi Wang, Min Li, Xiyue Yuan, Jihui Chen

    Background/Objectives: Voriconazole dosing in children is complicated by developmental and nonlinear pharmacokinetics, cytochrome P450 2C19 (CYP2C19) variation, variable oral bioavailability, inflammation, organ dysfunction, and drug interactions. We evaluated the characteristics, reporting completeness, and clinical applicability of pediatric and pediatric-inclusive voriconazole population pharmacokinetic (PopPK) models. Methods: PubMed, EMBASE, the Cochrane Library, Web of Science, and supplementary sources were searched from inception to 12 March 2026. Eligible studies developed a voriconazole PopPK model in patients aged 0–18 years or in a broader population with extractable or interpretable pediatric information. Reporting completeness was assessed using the 32-item Clinical Pharmacokinetic (ClinPK) checklist. Results: Eighteen studies published from 2004 to 2025 were included. Model-development cohorts contained 21–173 participants, and 15 studies reported 108–3336 concentrations. The median ClinPK reporting-completeness score was 82.6% (range, 74.2–90.0%). The included studies comprised one infant-specific, nine pediatric-only, six pediatric–young adult, and two mixed pediatric–adult models. Fifteen studies used parametric nonlinear mixed-effects methods and three used nonparametric methods; 15 selected two-compartment models and three selected one-compartment models. Body size was incorporated in 17 models and CYP2C19 phenotype was the most frequent retained covariate (10 models). Elimination structures, exposure targets, and dosing proposals were heterogeneous, and only one model underwent independent external validation. Conclusions: A population-matched model may support initial dosing, but early therapeutic drug monitoring and iterative Bayesian updating remain necessary. Current evidence does not support a universal pediatric model. Independent external validation and prospective implementation studies are required before routine clinical use.

  • Retraction
    Open Access

    Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer [Retraction]

    by Fang Bai, You Yin, Ting Chen, Jihui Chen, Meixin Ge, Yunshu Lu, Fangyuan Xie, Jian Zhang, Kejin Wu, Yan Liu

    Retraction for the article Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer

  • Open Access

    PopPK and PBPK Models Guide Meropenem Dosing in Critically Ill Children with Augmented Renal Clearance

    by Yao Liu, Hua He, Sa-Sa Zhang, Jia Zhou, Jin-Wei Zhu, Jin Xu, Hong-Jun Miao, Ji-Hui Chen, Kun Hao

    Background: Meropenem (MEM) is frequently prescribed for the empirical management of severe infections in the pediatric intensive care unit (PICU). Critically ill children exhibit substantial pharmacokinetic (PK) variability, and current dosing strategies remain inadequately evaluated, particularly in neonates, infants, and those with altered renal function. Methods: This study employed a dual modeling approach integrating population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) methodologies. Clinical data from two PICUs were utilized for PopPK model development and PBPK model evaluation. Both models were rigorously assessed using goodness-of-fit plots and prediction-based metrics. Monte Carlo simulations were subsequently conducted to calculate the probability of target attainment (PTA) for multiple dosing regimens across MICs of 0.25–16 mg/L. The pharmacodynamic target (PDT) was defined as maintaining unbound plasma concentrations above the MIC for 100% of the dosing interval (100% ƒT > MIC), and dosing regimens were considered acceptable if the PTA exceeded 90% for efficacy while avoiding potential toxicity (Css ≥ 50 mg/L). Results: A total of 202 MEM plasma concentrations from 101 pediatric patients were analyzed. Marked inter-individual variability in MEM pharmacokinetics and pharmacodynamics was observed. Augmented renal clearance (ARC) was frequently identified in PICU patients. We simultaneously developed a two-compartment population pharmacokinetic model incorporating body weight and estimated glomerular filtration rate, and a whole-body physiologically based pharmacokinetic model scaled from adults with adjustments for transporter ontogeny and renal function. The PopPK model, by incorporating interindividual variability on clearance and volume of distribution, captured a wider range of drug exposures and demonstrated superior predictive performance, particularly in subgroups with high eGFR. The PBPK model showed higher precision in the low eGFR subgroup but slightly lower overall predictive accuracy. Both models identified ARC as a key driver of subtherapeutic exposure. Standard regimens were insufficient for preterm neonates when the MIC was ≥4 mg/L, and even the maximum label-recommended dose failed to achieve the pharmacodynamic target for infants older than 1 month when the MIC was ≥2 mg/L. Conclusions: Both PBPK and PopPK frameworks reliably predicted MEM pharmacokinetics in critically ill pediatric patients, with complementary strengths across renal function strata. Model-informed simulations highlighted the inadequacy of standard dosing under conditions of ARC or elevated MIC, supporting individualized, precision-guided dosing strategies based on age, eGFR, and pathogen MIC.

  • Open Access

    Development of prediction models for carbapenem-resistant Klebsiella pneumoniae acquisition and prognosis in adult patients

    by Huijuan Yao, Yu Yang, Huimin Yao, Shuhong Bu, Lixia Li, Fang Wang, Jian Zhang, Jihui Chen

    Objectives: To explore the risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae (CRKP) infection and establish nomograms to predict the probability of CRKP infection and mortality in adult patients.Methods: Patients infected with KP from August 2019 to April 2021 in a tertiary hospital in Shanghai were enrolled. Risk factors associated with CRKP and 30-day mortality were identified using multivariate logistic regression analysis and Cox regression analysis.Results: Overall, 467 patients with KP infection were enrolled, wherein 210 (45.0%) patients were infected with CRKP and 257 (55.0%) patients with carbapenem-susceptible K. pneumoniae (CSKP). Five factors, namely Charlson’s Comorbidity Index (CCI) ≥ 3, the use of central venous catheterization, prior hospitalization during the 3 months before infection, and previous exposure to carbapenems and broad-spectrum β-lactams, were found to be independently associated with CRKP infection. Based on these parameters, the nomogram showed a better performance as indicated by C-index of 0.94 (95% confidence interval [CI]: 0.92–0.96) and well-fitted calibration curves. CRKP was independently associated with 30-day mortality. Multivariate Cox regression analysis revealed that age ≥65 years, higher CCI scores, higher Sequential Organ Failure Assessment scores, the presence of respiratory failure, albumin levels ≤30 g/L, and non-appropriate treatments in 3 days, were associated with 30-day mortality.Conclusion: The predictive nomogram established in this study can facilitate the clinicians to make better clinical decisions when treating patients with KP infection.


  • Open Access

    Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China

    by Lixia Li, Xiaohui Huang, Jingxian Liu, Chao Li, Zhiyan Lin, Rongrong Ren, Yan Zhang, Haoshu Ding, Jihui Chen, Yanfei Mao

    Background: Polymyxin B (PMB)-based combination therapies are used to treat severe carbapenem-resistant gram-negative bacterial (CR-GNB) infections. This observational study investigated the relationship between clinical factors, including PMB concentration, and clinical efficacy and safety. Patients and Methods: Polymyxin B regimens were optimized through therapeutic drug monitoring (TDM) and area under the concentration-time curve (AUC). In all, 382 samples were tested from 130 patients. Logistic regression was used to analyze the relationships between variables with clinical efficacy and 30-day mortality factors were analyzed by Cox regression. The sensitivity and specificity of Cmin and AUC for the occurrence of acute kidney injury (AKI) were determined by ROC curve analysis. Results: The clinical effectiveness of PMB was 65.4%. Multivariate logistic regression analysis revealed that lung infection, continuous renal replacement therapy, and C-reactive protein were independent factors significantly associated with efficacy. AKI occurred in 14.6% of the patients during treatment; age > 73 years (OR: 3.63; 95% CI: 1.035– 12.727; P = 0.044), Cmin greater than 2.3 μg/mL (OR: 7.37; 95% CI: 1.571– 34.580; P = 0.011), combined vancomycin (OR: 9.47; 95% CI: 1.732– 51.731; P = 0.009), and combined piperacillin-tazobactam (OR: 21.87; 95% CI: 3.139– 152.324; P = 0.002) were independent risk factors. The identified PMB cut-offs for predicting AKI were Cmin = 2.3 μg/mL and AUC = 82.0 mg h/L. Conclusion: Polymyxin B-based combination regimens are effective in treating CR-GNB infections, particularly bloodstream infections, but have shown unsatisfactory for lung infections. Cmin ≥ 2.3 μg /mL and AUC ≥ 82.0 mg h/L may increase PMB-associated AKI incidence. PMB dose should be adjusted based on TDM to ensure efficacy.


  • High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study

    by Xiaoxiao Chen, Jing Li, Liting Yu, Wenting Hu, Jiaoyang Cai, Zhuo Wang, Changcheng Chen, Xin Zhang, Yangyang Xie, Kefei Wu, et al.

    Summary: This study delivers a comprehensive evaluation of the efficacy and pharmacokinetics of high‐dose methotrexate (HDMTX) in a large cohort of Chinese paediatric acute lymphoblastic leukaemia patients. A total of 533 patients were included in the prognostic analysis. An association was observed between lower steady‐state MTX concentrations (MLL rearrangements. In contrast, such an association did not emerge within the low‐risk patient group. Additionally, utilizing population pharmacokinetic modelling (6051 concentrations from 815 patients), we identified the significant impact of physiological maturation, estimated glomerular filtration rate, sex and concurrent dasatinib administration on MTX pharmacokinetics. Simulation‐based recommendations include a reduced dosage regimen for those with renal insufficiency and a specific 200 mg/kg dosage for infants under 1 year. The findings underscore the critical role of HDMTX in treating IR/HR populations and call for a reassessment of its application in lower‐risk groups. An individualized pharmacokinetic dosage regimen could achieve the most optimal results, ensuring the largest proportion of steady‐state concentrations within the optimal range.


  • Open Access

    Factors influencing delayed high-dose methotrexate excretion and its correlation with adverse reactions after treatment in children with malignant hematological tumors

    by Liting Yu, Jiayi Shen, Haonan Li, Min Zhang, Zhuo Wang, Yijin Gao, Jihui Chen, Junyu Li

    Original Article Factors influencing delayed high-dose methotrexate excretion and its correlation with adverse reactions after treatment in children with malignant hematological tumors Liting Yu, Jiayi Shen, Haonan Li, Min Zhang, Zhuo Wang, Yijin Gao, Jihui Chen, Junyu Li


  • Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease

    by Tong Zhu, Xiaohui Huang, Hongyan Zhu, Jihui Chen, Huijuan Yao, Yufeng Zhang, Haibing Hua, Jian Zhang, Jia Qi


  • Open Access

    Individualized medication model of vancomycin in patients with renal insufficiency using machine learning techniques

    by Jihui Chen, Jia Zhou, Xiaohui Huang, Jing Ma, Huijuan Yao, Lei Jin, Chunming Lyu, Ze Yu, Jinyuan Zhang, Xin Hao, et al.

    Objectives: Inappropriate dose of vancomycin can cause nephrotoxicity, which should be avoided in clinical, particularly in patients with renal insufficiency. We aim to use machine learning techniques to explore important variables influencing vancomycin dose in patients with renal insufficiency and establish an individualized medication model to benefit these patients. Methods: Vancomycin administration cases in patients with renal insufficiency were collected at Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine from May 2018 to March 2022. Sequential Forward Selection was used for feature selection. Eight machine learning algorithms were compared the predictive performance, including XGBoost, LightGBM, CatBoost, GBDT, RF, SVC, KNN, and Logistic Regression. The one with the best predictive performance was chosen to calculate the importance score of modeling variables and establish the individualized medication model. Dose subgroups were divided into 500 mg, 1000 mg, 1500 mg and 2000 mg. Subgroup analysis based on the modeling variables were conducted. Results: This study included 237 eligible patients with 351 vancomycin cases. Six important variables were screened out, including gender, weight, AUC, uric acid, creatinine and total protein. CatBoost was chosen with the best prediction performance (accuracy=0.59) for modeling. The individualized medication model had precision over 53% and recall rate over 50% among all dose subgroups. The prediction of 1500 mg vancomycin had the best precision (65%), recall rate (71%) and F1-score (0.68). Conclusion: The individualized medication model of vancomycin for patients with renal insufficiency has good predictive performance, which can help clinicians make better decision of vancomycin use.

  • Open Access

    Evaluation of in vivo antibacterial drug efficacy using Caenorhabditiselegans infected with carbapenem-resistant Klebsiella pneumoniae as a model host

    by Huijuan Yao, Ajing Xu, Jingxian Liu, Fang Wang, Huimin Yao, Jihui Chen

    Objective: This study was developed to assess the in vivo antimicrobial activity of specific drugs using a model system consisting of Caenorhabditis elegans (C. elegans) infected with Carbapenem-resistant Klebsiella pneumoniae (CRKP) in an effort to identify promising drugs for CRKP-infected patient treatment.Methods: A C. elegans-CRKP liquid assay platform was developed and used to conduct limited in vivo screening for antimicrobial agents with potential activity against CRKP. Time curves for 10 different concentrations of tested antimicrobial agents were tested in this model system at 0, 2, 6, 8, and 12 h after treatment. The protective effects of these different antimicrobial agents were compared at different time points. Furthermore, ten CRKP strains samples were isolated from clinical specimens to demonstrate the applicability of the nematode model method, and two typical clinical cases are presented.Results: CRKP bacteria were sufficient to induce C. elegans death in a dose- and time-dependent fashion, while effective antimicrobial agents improved the survival of these nematodes in a dose-dependent manner. Notably, PB and TGC exhibited robust antibacterial protection within 12 h even at low tested concentrations, and clear efficacy remained evident for high doses of CAZ at this same time point as mediators of improved nematode survival. The results of C. elegans model method were well consistent with that using the Kirby-Bauer method in 10 CRKP strains samples, and two typical clinical cases showed applicability, reliability and efficacy of C. elegans model method.Conclusion: Overall, nematode models in drug sensitivity testing have shown advantages in clinical settings. Our results highlight the value of C. elegans model systems as tools for the simultaneous screening of different agents for in vivo antibacterial efficacy and are deserved further study.